Are growth factors the answer?

Shilpa Ramaswamy, Jeffrey H. Kordower

Research output: Contribution to journalArticlepeer-review

14 Scopus citations


Growth factors are potentially major players in therapeutic interventions for neurodegenerative disorders like Parkinson's disease (PD) because of their potential to not merely provide symptomatic relief but also be disease modifying agents. Many extensively utilized therapies such as the prodrug levodopa, while unquestionably effective, are intended for symptomatic benefit. Such therapies do little to stifle the progressive nature of these diseases thereby placing temporal restrictions on their effectiveness. Growth factors, by virtue of their distinct neuroprotective properties, have the cumulative effect of curbing disease progression and allaying existing symptoms. The purpose of this review is to discuss some of the growth factors commonly used in animal models of PD and those already used in clinical trials.

Original languageEnglish (US)
Pages (from-to)S176-S180
JournalParkinsonism and Related Disorders
Issue numberSUPPL. 3
StatePublished - Dec 2009
Externally publishedYes


  • GDNF
  • Gene therapy
  • Neurturin
  • Parkinson's disease
  • Trophic factors

ASJC Scopus subject areas

  • Neurology
  • Geriatrics and Gerontology
  • Clinical Neurology


Dive into the research topics of 'Are growth factors the answer?'. Together they form a unique fingerprint.

Cite this